Aegis Descent instal the last version for ios

Autopsy examination of the brain confirmed the clinical diagnosis of AD in 87% of autopsied cases. Data from the annual evaluations of up to eight years of African American and White patients (N = 1,094) and nondemented control subjects (N = 463) recruited by these sites constitute the CERAD database. With input from 24 NIA-sponsored Alzheimer’s Disease Research Centers and other university programs in the US, CERAD developed brief clinical, neuropsychology, neuroimaging, and neuropathology batteries, which were then utilized by these sites. When CERAD was initiated, there was general acceptance of the diagnostic criteria for Alzheimer’s disease (AD), but the multitude of cognitive assessment measures used in different combinations across memory disorders clinics did not facilitate aggregation of information, and resulted in reduced power to explore AD or dementias classified as AD. ĬERAD’s mandate was to develop brief, valid and reliable measures to standardize the evaluation and diagnosis of patients with AD.

A previous review paper provided information on the first 20 years of experience with all the measures.

Of all the measures of the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD PI Albert Heyman, MD), the neuropsychology battery has withstood the test of time, enjoyed extensive and varied use, and is the focus here.

Aegis Descent instal the last version for ios